BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'market Day'. (Return)

MarketWatch MarketPulseJun 17, 2019
Adaptive Biotechnologies sets terms for IPO, to raise up to $212.5 million
Adaptive Biotechnologies Corp. set terms for its initial public offering Monday, in which the developer of immune-system derived disease treatments is expected to raise up to $212.5 million and be valued at about $2.01 billion. The Seattle-based company is offering 12.5 million shares in the IPO, which is expected to price between $15 and $17 a share. If the underwriters, led by Goldman Sachs, J.P. Morgan and BofA Merrill Lynch, exercise all options to buy 1.875 million additional shares, the company could raise up to $244.4 million and be valued at up to $2.05 billion. The stock is expected to list on the Nasdaq under the ticker symbol "ADPT." The underwriters are led by Goldman Sachs, Citigroup and Wells Fargo Securities. After the IPO, the company will have about 118.5 million shares outstanding. The company recorded a net loss of $46.3 million on revenue of $55.7 million in 2018, after a loss of $42.5 million on $38.4 million in revenue in 2017. The company is looking to go public at a time that the iShares Nasdaq Biotechnology ETF has gained 10% year to date and the S&P 500 has advanced 15%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseJun 17, 2019
BridgeBio Pharma to raise up to $240 million, as terms set for IPO
BridgeBio Pharma Inc. disclosed Monday that it set terms for its initial public offering, in which the drug discovery company to treat genetic diseases is expected to raise up to $240 million and be valued at about $1.84 billion. The Palo Alto, Calif.-based company is offering 15 million shares in the IPO, which is expected to price between $14 and $16 a share. If the underwriters, led by J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR, exercise all options to buy additional shares, BridgeBio could raise up to $276.0 million and be valued at up to $1.88 billion. The stock is expected to list on the Nasdaq under the ticker symbol "BBIO." After the IPO, the company will have about 115 million shares outstanding. The company recorded a net loss of $144.0 million in 2018, after a loss of $36.2 million in 2017. The company is looking to go public at a time that the Renaissance IPO ETF has gained 35.6% year to date and the S&P 500 has advanced 15.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatchJun 17, 2019
Bond Report: Treasury yields struggle for direction ahead of busy week for central bankers
Treasury yields are mixed on Monday ahead of meetings this week for the Federal Reserve, the European Central Bank and the Bank of Japan

RELATED ARTICLES
Global stocks, yields steady with Fed, central bank meetings on tap (Reuters Business)

MarketWatch MarketPulseJun 17, 2019
Blockchain company Ripple invests in MoneyGram to power cross-border payments, shares explode higher
Blockchain company Ripple announced an investment in and partnership with MoneyGram International Inc. Monday afternoon, sending MoneyGram shares soaring more than 100%. Ripple, which is known for its XRP cryptocurrency and blockchain technology, agreed to purchase $30 million worth of freshly created MoneyGram shares at $4.10 apiece, and can purchase another $20 million more at its discretion at a minimum of $4.10. MoneyGram shares closed Monday at $1.45, but exploded higher after the announcement, recently topping $3 in after-hours trading. The cost of an XRP coin jumped more than 5% immediately after the announcement. MoneyGram will use Ripple's XRP technology to handle cross-border transfers of digital funds for at least two years under the deal. "Through this strategic partnership, MoneyGram will be able to settle key currencies and match the timing of funding with its settlement requirements, reducing operating costs, working capital needs and improving earnings and free cash flow," MoneyGram said in the announcement.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseJun 17, 2019
Social-media stocks, telecom shares lead stock market to narrow win ahead of Fed meeting
U.S. stocks eked out modest to slight gains on Monday, powered by a climb in shares of technology-related and communication services shares. The Dow Jones Industrial Average closed up 0.1% at 26,112, picking up 23 points, the S&P 500 index rose 0.1% to 2,890, while the Nasdaq Composite Index advanced 0.6% to 7,845. The gains came as a gauge of manufacturing activity in the New York area, the Empire State manufacturing index, plummeted 26.4 points to negative 8.6 in June, a record decline. Economists had expected a reading of positive 10, according to a survey by Econoday. The weak survey data come as the Federal Reserve commences its two-day policy meeting Tuesday, where the central bank may indicate its willigness to reduce benchmark borrowing costs amid fears of the fallout from global trade tensions and a slowdown in the economy. In corporate news, shares of Facebook Inc. gained as interest grew around its reported cryptocurrency offering, Libra coin, set to debut on Tuesday.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseJun 17, 2019
Karuna Therapeutics sets IPO terms, to be valued at up to $363 million
Karuna Therapeutics Inc. set terms Monday for its initial public offering, in which the biopharmaceutical company developing treatments for neuropsychiatric conditions is expected to raise up to $74.4 million and be valued at about $363.3 million. The company is offering 4.375 million shares in the IPO, which is expected to price between $15 and $17 a share. The stock is expected to list on the Nasdaq under the ticker symbol "KRTX." The company said some existing shareholders and directors have expressed interest in buying up to a combined $30 million of shares at the IPO price. The underwriters are led by Goldman Sachs, Citigroup and Wells Fargo Securities. After the IPO, the company will have about 21.4 million shares outstanding. The company recorded a net loss of $17.5 million on no revenue in 2018, after a loss of $6.0 million on no revenue a year ago. The company is looking to go public at a time that the iShares Nasdaq Biotechnology ETF has lost 7.2% over the past three months, while the Renaissance IPO ETF has gained 3.2% and the S&P 500 has gained 2.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



RELATED ARTICLES
Priam Properties sets terms for IPO, to raise up to $180 million (MarketWatch MarketPulse)

Google Business NewsJun 17, 2019
Dow Jones Futures: Stock Market Rally Hits Resistance; Facebook Stock Jumps, MoneyGram Skyrockets On Cryptocurrency News - Investor's Business Daily
Dow Jones Futures: Stock Market Rally Hits Resistance; Facebook Stock Jumps, MoneyGram Skyrockets On Cryptocurrency News  Investor's Business DailyRipple to Invest Up to $50M in MoneyGram Following New Partnership  CointelegraphRipple Takes $50 Million Stake in MoneyGram in Push to Deploy XRP  FortuneMoneyGram Announces Strategic Partnership with Ripple  PRNewswireRipple to Invest Up to $50 Million in MoneyGram  The Wall Street JournalView full coverage on Google News

MarketWatchJun 17, 2019
Market Snapshot: Stocks kick off week on positive note as social media, entertainment shares lead
U.S. stocks head higher Monday, led by gains in social media and entertainment shares such as Facebook Inc. and Netflix Inc.

MarketWatch MarketPulseJun 16, 2019
U.S. chip makers seek easing of Huawei ban: report
Major U.S. chip makers, including Intel Corp. , Qualcomm Inc. and Xilinx Inc. , have quietly lobbied the Trump administration to ease its ban on sales to Chinese tech giant Huawei Technologies Co., Reuters reported Sunday. One source told Reuters that the aim was not to help Huawei, but to prevent harm to U.S. companies. Reuters said Huawei spent about $11 billion buying components from U.S. companies in 2018. The Trump administration announced the ban in May, after trade negotiations between the U.S. and China stalled. Earlier this month, the acting White House budget chief sought to delay implementation of the ban, the Wall Street Journal reported, arguing that the burden would fall on U.S. companies that did business with Huawei.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


TRENDING TAGS
ChinaTariffs Trump UBS loses bond
StocksFed meeting higher Global yields
Fedmeeting stocks higher ahead Wall
Trumptariffs China interview trade Tariff
TariffsChina Trump Businesses plan will
SothebyDrahi Deal Billion Patrick buy
stockFed Market meeting higher ahead
DealBillion Sotheby Drahi Pfizer Array
ReportingLLC L J CAPITAL P
AmazonOcasio-Cortez wages tarvation Prime claim

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2019 CEOExpress Company LLC